A Proton Pump Inhibitor, E3810, Has Antibacterial Activity Through Binding to Helicobacter Pylori

Overview

Journal J Gastroenterol

Specialty Gastroenterology

Date 1995 Aug 1

PMID 7550855

Citations 9

Authors

M Hirai

T Azuma

S Ito

T Kato

Y Kohli

Affiliations

Soon will be listed here.

Abstract

Helicobacter pylori infection is causally related to atrophic gastritis, and it may also be associated with peptic ulcer and gastric carcinoma. Eradication of H.pylori is recommended in patients with such diseases, especially in those with peptic ulcer. A new potent proton pump inhibitor, E3810, had an antibacterial effect on H. pylori, as has been reported for omeprazole and lansoprazole, two other proton pump inhibitors. The minimum inhibitory concentration of E3810 was 1.57-3.13 micrograms/ml, lower than that of omeprazole or lansoprazole. To clarify the mechanism of the antibacterial effect of E3810, we analyzed the characteristics of E3810 binding to H. pylori. Scatchard plot analysis of this binding showed a curvilinear profile, indicating the presence of several molecules with different affinities to E3810 on H. pylori. The binding capacity of E3810 to H. pylori was calculated to be about 2 x 10(6) sites/cell. These results suggested that E3810 has an antibacterial effect against H. pylori and that the effect may be mediated through direct binding to H. pylori.

Citing Articles

The Possible Role of in Gastric Cancer and Its Management.

Alfarouk K, Bashir A, Aljarbou A, Ramadan A, Muddathir A, Alhoufie S Front Oncol. 2019; 9:75.

PMID: 30854333 PMC: 6395443. DOI: 10.3389/fonc.2019.00075.

Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Fisher L, Fisher A Clin Drug Investig. 2017; 37(7):587-624.

PMID: 28361440 DOI: 10.1007/s40261-017-0519-y.

Proton pump inhibitors alter the composition of the gut microbiota.

Jackson M, Goodrich J, Maxan M, Freedberg D, Abrams J, Poole A Gut. 2016; 65(5):749-56.

PMID: 26719299 PMC: 4853574. DOI: 10.1136/gutjnl-2015-310861.

Potent gastric acid inhibition in Helicobacter pylori eradication.

Gisbert J Drugs. 2005; 65 Suppl 1:83-96.

PMID: 16335862 DOI: 10.2165/00003495-200565001-00012.

Novel action of gastric proton pump inhibitor on suppression of Helicobacter pylori induced angiogenesis.

Yeo M, Kim D, Han S, Lee J, Kim Y, Cho Y Gut. 2005; 55(1):26-33.

PMID: 16127019 PMC: 1856363. DOI: 10.1136/gut.2005.067454.

References

Segal E, Shon J, Tompkins L . Characterization of Helicobacter pylori urease mutants. Infect Immun. 1992; 60(5):1883-9. PMC: 257089. DOI: 10.1128/iai.60.5.1883-1889.1992. View

Hentschel E, Brandstatter G, Dragosics B, Hirschl A, Nemec H, Schutze K . Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med. 1993; 328(5):308-12. DOI: 10.1056/NEJM199302043280503. View

Nagata K, Satoh H, Iwahi T, Shimoyama T, Tamura T . Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells. Antimicrob Agents Chemother. 1993; 37(4):769-74. PMC: 187756. DOI: 10.1128/AAC.37.4.769. View

Mauch F, Bode G, Malfertheiner P . Identification and characterization of an ATPase system of Helicobacter pylori and the effect of proton pump inhibitors. Am J Gastroenterol. 1993; 88(10):1801-2. View

Hunt R . pH and Hp--gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism. Am J Gastroenterol. 1993; 88(4):481-3. View

Rauws E, Tytgat G . Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet. 1990; 335(8700):1233-5. DOI: 10.1016/0140-6736(90)91301-p. View

Marshall B, Goodwin C, Warren J, Murray R, Blincow E, Blackbourn S . Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet. 1988; 2(8626-8627):1437-42. DOI: 10.1016/s0140-6736(88)90929-4. View

Iwahi T, Satoh H, Nakao M, Iwasaki T, Yamazaki T, Kubo K . Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother. 1991; 35(3):490-6. PMC: 245037. DOI: 10.1128/AAC.35.3.490. View

van Zanten S, Goldie J, Hollingsworth J, Silletti C, Richardson H, Hunt R . Secretion of intravenously administered antibiotics in gastric juice: implications for management of Helicobacter pylori. J Clin Pathol. 1992; 45(3):225-7. PMC: 495478. DOI: 10.1136/jcp.45.3.225. View

10.

Labenz J, Ruhl G, Bertrams J, Borsch G . Medium- or high-dose omeprazole plus amoxicillin eradicates Helicobacter pylori in gastric ulcer disease. Am J Gastroenterol. 1994; 89(5):726-30. View

11.

Adamek R, Wegener M, Labenz J, Freitag M, Opferkuch W, Ruhl G . Medium-term results of oral and intravenous omeprazole/amoxicillin Helicobacter pylori eradication therapy. Am J Gastroenterol. 1994; 89(1):39-42. View

12.

SCATCHARD G . Some physical chemical aspects of plasma extenders. Ann N Y Acad Sci. 1952; 55(3):455-64. DOI: 10.1111/j.1749-6632.1952.tb26560.x. View

13.

McGowan C, Cover T, Blaser M . The proton pump inhibitor omeprazole inhibits acid survival of Helicobacter pylori by a urease-independent mechanism. Gastroenterology. 1994; 107(3):738-43. DOI: 10.1016/0016-5085(94)90121-x. View

14.

Blaser M . Gastric Campylobacter-like organisms, gastritis, and peptic ulcer disease. Gastroenterology. 1987; 93(2):371-83. DOI: 10.1016/0016-5085(87)91028-6. View

15.

Warren J, Marshall B . Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983; 1(8336):1273-5. View